23 articles with Xellia Pharmaceuticals
Today, Civica Rx announced it had inked a product supply agreement with Xellia Pharmaceuticals, where Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civica’s members.
Civica Rx (Civica, Inc.) and Xellia Pharmaceuticals today announced they have signed a product supply agreement under which Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civica’s member health systems.
Nichi-Iko Pharmaceutical Co., Ltd. and Sagent Pharmaceuticals, Inc. announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals.
Xellia Pharmaceuticals Divests Raleigh, North Carolina Production Facilities to Sagent Pharmaceuticals
Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections has entered into an agreement to divest Xellia’s Raleigh, North Carolina manufacturing plant to Sagent Pharmaceuticals Inc., (‘Sagent’), a leader of specialty pharmaceutical products with an emphasis on the injectable market.
Xellia Pharmaceuticals announced it has received U.S. Food and Drug Administration (FDA) approval for Premixed Vancomycin Injection in a Ready-to-Use (RTU) bag in the United States market.
Xellia Pharmaceuticals Announces the Launch of First US Market Product Vancomycin Hydrochloride for Injection, USP
Now offering Vancomycin HCl, USP 10 g and 1 g lyophilized powder in the United States market.
Xellia Pharmaceuticals Opens North American Commercial Office in Chicago Ahead of Launching Value-Added Anti-Infective Injectable Drug Products
New anti-infective products to launch in US hospital markets.
LEUKOCARE and Xellia Pharmaceuticals partner to discover innovative formulations for the development of value-added anti-infective therapies
LEUKOCARE AG and Xellia Pharmaceuticals, have entered into a global strategic partnership, where both companies will collaborate closely to discover innovative and superior formulations to support the development of Xellia’s pipeline of value-added antibiotic and antifungal products which are intended to enhance patient care.
Xellia Pharmaceuticals Appoints Craig Boyd as President, Xellia US as it Expands its Commercial Organization in Preparation for the Launch of its Value-Added Anti-Infective Drug Products
Xellia Pharmaceuticals announced that it has appointed Craig Boyd to the new leadership role of President, Xellia US.
Xellia Pharmaceuticals Reports on Strong 2017 Financial Results and Advances in the Development of its Novel Premixed Vancomycin Ready-to-Use (RTU) Bag
Xellia Pharmaceuticals reported its financial results for the year ending December 31, 2017 and provided an update on its product portfolio.
Xellia Expands Its Global Specialty Anti-Infective Product Manufacturing Capabilities With A US $25 MIllion Investment In Its Copenhagen Site
Xellia Completes Expansion Of Its Budapest Facilities, Strengthening Its Global Anti-Infective Product Capabilities
Xellia Commences Packaging And Distribution Operations At Cleveland Site after Successful FDA Inspection
Xellia Expands Croatian Anti-Infective Product And Innovation Capabilities To Tackle Antimicrobial Resistance Crisis
Xellia Pharmaceuticals Focuses On Innovation In Anti-infectives With Formation Of Scientific Advisory Board
Xellia Pharmaceuticals Strengthens Commitment To Innovation In Anti-Infectives With New API R&D Center Of Excellence In Oslo